The idea of considering PAPP-A as a therapeutic target in atherosclerosis first emerged from its abundant expression in coronary plaques that had ruptured or eroded in patients, who experienced sudden cardiac death [22]. The gene discussed is PAPPA; the disease is atherosclerosis.